Thus, general targeting of CD47 by using antibody strategy is likely to induce important adverse events, such as phagocytic-induced severe anemia, thrombocytopenia and splenomegaly, as previously reported during non-clinical work [14,15], as well as in Phase I clinical trials [16]. The gene discussed is CD47; the disease is Splenomegaly.